Vericel Beats on Q3, Raises 2026 Revenue Guidance to $344-$346M
VCEL sits 69% above its 52-week low of $28.95 on elevated volume (3.3× avg).
Summary
Vericel reported Q3 revenue of $85.4M (up 26%) and net income of $14.2M (up 179%), then raised full-year revenue guidance to $344-$346M and its adjusted EBITDA margin target to 28%.
Key Events · Earnings and Guidance · VCEL
-
Q3 Revenue Up 26% to $85.4M
MACI revenue rose 21% to $67.4M and Burn Care rose 52% to $18.0M, including $3.0M of BARDA procurement revenue.
-
Net Income Up 179% to $14.2M
Diluted EPS was $0.27 versus $0.10 a year ago; adjusted EBITDA rose 48% to $25.2M, or 30% of revenue.
-
Full-Year Guidance Raised
Revenue guidance lifted to $344-$346M from $330-$340M; Burn Care to $54M from $46-$50M; adjusted EBITDA margin to 28% from 27%.
-
Buyback Continues
Repurchased 220,744 shares for $8.8M in Q3, with $191.2M of authorization remaining as of September 30, 2026.
Analysis · VCEL · Life Sciences
Vericel's Q3 revenue grew 26% to $85.4M and net income jumped 179% to $14.2M ($0.27 per diluted share), with adjusted EBITDA at 30% of revenue. Management raised full-year revenue guidance to $344-$346M from $330-$340M and lifted the adjusted EBITDA margin target to 28% from 27%, citing a strong start to Q4 in both MACI and Burn Care. The company also bought back 220,744 shares for $8.8M in the quarter, leaving $191.2M of authorization, and holds $235.6M in cash and investments with no debt. The stock is trading near its 52-week high of $49.32, so the raised guidance is the key test of whether that level holds.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VCEL was trading at $48.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $28.95 to $49.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.